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arginina-vasopressina neurofisina II de pacientes com  
diabetes insípido central idiopático com longo seguimento
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ABSTRACT
Introduction: Central diabetes insipidus (DI) characterized by polyuria, polydipsia and inability 
to concentrate urine, has different etiologies including genetic, autoimmune, post-traumatic, 
among other causes. Autosomal dominant central DI presents the clinical feature of a progres-
sive decline of arginine-vasopressin (AVP) secretion. Objective: In this study, we characterized 
the clinical features and sequenced the AVP-NPII gene of seven long-term follow-up patients 
with idiopathic central DI in an attempt to determine whether a genetic cause would be invol-
ved. Methods: The diagnosis of central DI was established by fluid deprivation test and hyper-
tonic saline infusion. For molecular analysis, genomic DNA was extracted and the AVP-NPII 
gene was amplified by polymerase chain reaction and sequenced. Results: Sequencing analy-
sis revealed a homozygous guanine insertion in the intron 2 (IVS2 +28 InsG) of the AVP-NPII 
gene in four patients, which represents an alternative gene assembly. No mutation in the code 
region of the AVP-NPII gene was found. Conclusions: The homozygous guanine insertion in 
intron 2 (IVS2 +28 InsG) is unlikely to contribute to the AVP-NPII gene modulation in DI. In addi-
tion, the etiology of idiopathic central DI in children may not be apparent even after long-term 
follow-up, and requires continuous etiological surveillance. Arq Bras Endocrinol Metab. 2010;54(3):269-73 
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RESUMO
Introdução: O diabetes insípido (DI) central, caracterizado por poliúria, polidipsia e inabilida-
de em concentrar a urina, apresenta diferentes etiologias, incluindo causas genética, autoi-
mune, pós-traumática, entre outras. O DI central autossômico dominante apresenta a carac-
terística clínica de falência progressiva da secreção da arginina-vasopressina (AVP). Objetivo: 
No presente estudo, caracterizou-se a apresentação clínica e sequenciou-se o gene AVP-NPII 
de sete pacientes com DI central idiopático seguidos de longa data na tentativa de determinar 
se uma causa genética estava envolvida na etiologia. Métodos: O diagnóstico do DI central 
foi estabelecido por meio do teste de jejum hídrico e infusão de salina hipertônica. Para a rea-
lização da análise molecular, o DNA genômico foi extraído e o gene AVP-NPII foi amplificado 
pela reação em cadeia da polimerase e, posteriormente, sequenciado. Resultados: A análise 
do sequenciamento do gene AVP-NPII revelou uma inserção em homozigose de uma guanina 
no íntron 2 (IVS2 +28 InsG) em quatro pacientes, correspondendo a um arranjo alternativo do 
gene. Nenhuma mutação da região codificadora do gene AVP-NPII foi encontrada. Conclu-
sões: A inserção em homozigose de uma guanina no íntron 2 (IVS2 +28 InsG) provavelmente 
não contribui na modulação do gene AVP-NPII no DI. Adicionalmente, a etiologia do DI central 
idiopático em crianças pode não se tornar evidente mesmo após um longo período de segui-
mento, necessitando de contínua vigilância da etiologia. Arq Bras Endocrinol Metab. 2010;54(3):269-73
Descritores
Diabetes insípido central; gene AVP-NPII; PCR; sequenciamento; mutação
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InTRODUCTIOn
Central diabetes insipidus (DI) is a heterogeneous disease characterized by polyuria and polydipsia 
and failure to concentrate urine leading to a conse-
quent excretion of large volumes of dilute urine. It is 
caused by a deficient secretion of arginine-vasopressin 
(AVP) by the neurohypophysis (1).
Although rare, familial inherited forms account for 
some cases of central DI (2-4). Genetic causes of cen-
tral DI are usually due to gene mutations that encode 
AVP and its intracellular binding protein, neurophysin-
II (AVP-NPII gene) and include autosomal dominant 
(2) and recessive forms (5). The AVP-NPII gene is 
located on chromosome 20 and contains three exons: 
exon 1 encodes the signal peptide, AVP peptide and 
the amino-terminal region of neurophysin-II; exon 2 
encodes the central region of neurophysin-II; and exon 
3 encodes the carboxy-terminal region of neurophysin-
II and co-peptin, a glycoprotein (6). Most of the mu-
tations causing autosomal dominant central DI have 
been described in the gene portion encoding neuro-
physin-II (2,7,8), leading to an improper folding and 
dimerization of neurophysin-II which accumulates in 
the endoplasmic reticulum (3,9,10). The onset of vaso-
pressin deficiency in autosomal dominant familial cen-
tral neurohypophyseal DI (adFNDI) usually becomes 
gradually apparent during the first decade of life, and 
is associated with a progressive degeneration of vaso-
pressin-producing magnocellular neurons in the supra-
optic and paraventricular nuclei of the hypothalamus 
(2,8,11). The neuron degeneration is probably due to 
a cytotoxic effect of the retained vasopressin-neurophy-
sin-II in the magnocellular neurons (3,9,12). In addi-
tion, the dimerization between the wild type and the 
mutant precursors may occur, leading to a dominant 
negative mechanism that may contribute to the patho-
genesis of adFNDI (13). 
The destruction or degeneration of vasopressiner-
gic neurons can be due to different acquired etiolo-
gies such as intrasellar tumors, granulomatous disease, 
trauma, inflammatory and vascular disease (1). Never-
theless, central DI is still considered idiopathic in 15% 
to 50% of patients (14-16) and its etiology should be 
pursued, especially in those patients with other ante-
rior pituitary deficiencies and pituitary stalk thicken-
ing (17). Therefore, periodic clinical, laboratorial and 
imaging evaluations by magnetic resonance imaging 
(MRI) are required during the follow-up of patients 
with idiopathic central DI in order to rule out associ-
ated anterior pituitary deficiencies or cerebral diseases 
(17,18). However, even after long-term follow-up, the 
etiology of the so-called idiopathic central DI remains 
not established in many patients (19). In the present 
study we aimed to evaluate the clinical presentation 
and the molecular analysis of the AVP-NPII gene in 
patients with idiopathic central DI with onset of symp-
toms during childhood. 
PATIEnTS AnD METhODS
We studied seven patients (5 male, 2 female) with idio-
pathic central DI after obtaining informed consent and 
the approval of the University Hospital Ethics Commit-
tee. The diagnosis of central DI was based on the fluid 
deprivation test (20) or on hypertonic saline infusion 
(21). Anterior pituitary function was evaluated at base-
line or stimulated pituitary hormone measurements us-
ing standard previously published immunoassays (22). 
Central nervous system MRI was performed in all 
but one patient who was lost to follow-up in 1995, be-
fore the technique was available at the hospital. 
Molecular analysis
Genomic DNA was extracted from peripheral blood 
samples using a QIAmp kit (Qiagen Inc., Valencia, 
CA, USA), and the AVP-NPII gene was amplified by 
polymerase chain reaction (PCR) using specific prim-
ers. For exon 1, the sense TGG CGG CCG CGT CTC 
GCC TCC ACG GGA ACA and antisense GCT ATG 
GCT GCC CTG AGA TGG CCC ACA GTG primers, 
were used; for exons 2 and 3 and their intronic region, 
the sense TCG CTG CGT TCC CCT CCA ACC CCT 
CGA CTC and antisense CCT CTC TCC CCT TCC 
CTC TTC CCG CCA GAG primers, were used. The 
PCR reaction was carried out with 10% DMSO, using 
the hot start method followed by forty cycles of amplifi-
cation (exon 1: 1 minute at 95°C, 1 minute at 66°C and 
1 minute at 72°C; exons 2 and 3: 1 minute at 95°C, 1 
minute at 60°C and 1 minute at 72°C). PCR products 
were visualized in 1% agarose gel followed by automat-
ed sequencing (ABI 377; Applied Biosystems). DNA 
sequencing was compared to data described by Bahnsen 
and cols. (23) (GenBank access number X62890).
RESUlTS 
Clinical and laboratory findings of studied patients are 
presented in table 1. None of the patients had family 
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Table 1. Clinical, radiological and laboratory data for patients with central diabetes insipidus
Patient Age at 
diagnosis 
(years)/ 
Genre
Follow-up 
(years)
Familial 
history
Diuresis 
(ml/kg/d)
Basal 
serum 
sodium
Basal 
pOsm
Basal 
uOsm
Maximum 
pOsm 
post-
dehydrata-
tion 
Maximum 
uOsm 
post-
dehydrata-
tion 
Dehydra-
tation 
duration 
time 
(hours)
Minimum 
pOsm 
post-
desmo-
pressin 
Maximum 
uOsm 
post-
desmo-
pressin 
Image (MRI)
1 3.6/M 28 Present 250 143 296 72 307 291 6 295 466 Normal hypophysis 
volume
Bright spot not present
2 3.7/F 30 Absent 320 135 296 64 – 84 2 300 600 N/A
3 6/M 34 Present – 147 300 298 – – – – – Reduced hypophysis 
volume
Progressive bright 
spot loss
4 7/M 7 Absent 143 143 289 51 294 50 3 281 180 Normal hypophysis 
volume
Bright spot not present
5 5.8/M 28 Absent 150 150 286 46 318 52 6 280 502 Normal hypophysis 
volume
Progressive bright 
spot loss
6 7.5/M 16 Absent 200 144 291 70 – – – – – Normal hypophysis 
volume
mild infundibulum 
thickness
Progressive bright 
spot loss
7 1/F 10 Absent 206 127 293 64 294 591 8 290 717 Normal hypophysis 
volume
Bright spot not present
M: male; F: female; pOsm: plasma osmolality; uOsm: urinary osmolality; MRI: magnetic resonance image. 
history of diabetes insipidus except patients 1 and 3 who 
were third-degree cousins but had no other relatives af-
fected. Also, no autoimmune disease was identified in 
any of the nine patients. Age at onset of polyuria and 
polydipsia varied from 1 to 7 years of age, and dura-
tion of symptoms at diagnosis varied between 2 months 
and 5 years. Polyuria and polydipsia were the presenting 
symptoms in all patients, whose urinary volume at diag-
nosis ranged from 3 to 13.3 L/24h (143 to 320 mL/
kg/day). The fluid deprivation test and vasopressin ana-
log responses were consistent with the diagnosis of total 
central DI in all but one patient that had a response 
compatible with partial central DI (Patient 6). Growth 
retardation and bone age delay were observed in pa-
tients 1 and 7. Adrenal and thyroid functions and pu-
bertal development were normal in all patients. Patients 
were followed for 22 years at our out-patient clinic. 
No expansive sella turcica lesions were visualized 
by imaging study in any patient, except patient 6 who 
showed mild infundibulum thickness and a pars inter-
media cyst, which disappeared during follow-up. Initial 
sella turcica MRI studies in six patients resulted in the 
absence of the posterior pituitary hyperintense signal 
in three patients and its presence in three patients also; 
which lost the bright spot of the neurohypophysis in 
subsequent MRI during follow-up. Only one patient 
showed a reduced anterior pituitary. 
Sequencing of AVP-NPII gene revealed no muta-
tions in exons 1, 2 and 3 in any patients. However, a 
homozygous insertion of an additional guanine in in-
tron 2 (IVS2 +28 InsG) was found in 4 patients. Due 
to the latter finding, we also sequenced AVP-NPII 
gene from controls and the same insertion in intron 2 
was found in three out of nine controls. 
DISCUSSIOn
In this study we presented seven patients with central 
DI diagnosed during the infancy with no apparent eti-
ology after long-term follow-up. Molecular analysis of 
AVP-NPII gene showed no mutations in the coding 
region of this gene. 
In the present series the age of onset for symptoms 
of polyuria and polydipsia was between 1 and 7 years 
of age, median of 5.8 years, very similar to the median 
age of 6.4 years reported by Maghnie and cols. (16) in 
a multi-centric study of pediatric patients with central 
DI. In our cohort, all patients but one were diagnosed 
within 6 months after the onset of symptoms. The liter-
ature usually describes a more dilated latency between 
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the onset of symptoms and the diagnosis, with previ-
ous reports showing an interval of 4 years (24). The 
delay of the diagnosis of diabetes insipidus in pediatric 
patients suggests that clinicians may not be aware of 
the need to investigate the symptoms of polyuria and 
polydipsia in children. 
Growth retardation and bone age delay were ob-
served in patients 1 and 7, which are in accordance with 
the 20% to 35% of patients with idiopathic central DI 
and short stature previously described (16,24,25). 
All seven patients in this series had no clear etiology 
for the vasopressin deficiency, despite the follow-up of 
3 to 34 years. In an attempt to uncover the etiology of 
the disease in these patients, we carried out molecular 
analysis of the AVP-NPII gene. Although we found no 
mutation in the AVP-NPII gene in this series of DI 
patients, Rutishauser and cols. (10) previously reported 
a de novo AVP-NPII gene mutation in a patient with 
early onset of central DI and no family history, suggest-
ing that genetic testing may be useful in patients who 
develop idiopathic DI during childhood.
While no mutation in the coding region was found, 
we identified a homozygous guanine insertion in intron 
2 (IVS2 +28 InsG) in 4 patients. This insertion has also 
been described by Bahnsen and cols. (23) (GenBank 
access X62891) with a concomitant mutation in the 
coding region (Gly57Ser). As the authors performed 
direct gene sequencing in only one member of the kin-
dred of 6 affected members, we do not know whether 
the G insertion was also present in their other patients 
or non-affected individuals, and the authors do not 
discuss this particular issue. Moreover, an error due to 
PCR/sequencing technique problems is less likely to 
account for our findings since the result was found in 
both, sense and antisense sequences as well as in repeat-
ed PCR experiments. Indeed, finding the G insertion in 
3 out of 9 controls indicated that this variation might 
represent an alternative gene assembly that is unlikely 
to contribute to the AVP-NPII gene modulation (26).
The presence of vasopressin-secreting cell autoan-
tibodies in association with pituitary stalk thickening 
suggests autoimmunity in almost 100% of patients with 
apparent idiopathic central DI (27). However, circu-
lating human hypothalamus vasopressin-secreting cell 
autoantibodies have also been reported in patients with 
different causes of central DI (19,27-29), including 
Langerhans cell histiocytosis and germinoma; therefore, 
the presence of these antibodies may not be a reliable 
marker of autoimmune central DI (29). In the present 
study, determination of autoantibodies to vasopressin 
secreting cells was not available, therefore, we could not 
rule out an autoimmune cause of central DI, especially 
in patient 6, who showed pituitary stalk thickness.
Although, pituitary stalk thickening in patients with 
central DI can be reversible and transient, as reported 
by De Buyst and cols. (24), the finding of pituitary stalk 
thickening in patients with central DI strongly indicates 
the need for long-term follow-up, since organic cause 
of central DI, such as germinoma and Langerhans cell 
histiocytosis, has been associated with isolated central 
DI with pituitary stalk thickening (18,30). 
In the present study, brightness signal of the poste-
rior lobe on magnetic resonance T1-weighted images 
was absent in five patients. The absence of posterior pi-
tuitary bright signal has been associated with central DI 
(31-33). On the other hand, presence of the signal may 
not indicate normal vasopressin secretion (31). Maho-
ney and cols. (34) studied the kindred with adFNDI by 
magnetic resonance imaging and showed the presence 
of the posterior pituitary hypertensive signal in all af-
fected children, but an absent or barely visible signal in 
all adult patients but one, suggesting a progressive loss 
of the posterior pituitary signal in this inherited form of 
DI. In fact, three out of six patients in the current study 
presented a normal posterior pituitary signal, which dis-
appeared later during follow-up, indicating progressive 
development of MRI features, similar to the decrease in 
AVP secretion (8). 
It is important to point out that vascular abnormal-
ity should also be considered as a plausible cause of 
vasopressin deficiency in the present series of patients, 
since abnormal arterial blood flow affecting posterior 
pituitary blood supply has been previously described in 
patients with idiopathic central DI and normal anterior 
pituitary and pituitary stalk size with absence of poste-
rior pituitary bright signal in the MRI (35). 
In conclusion, we found a homozygous guanine in-
sertion in intron 2 (IVS2 +28 InsG) in the AVP-NPII 
gene in DI patients as well as in controls, suggesting an 
alternative gene assembly that is unlikely to contribute 
to the AVP-NPII gene modulation. In addition, we con-
firm that the etiology of idiopathic central DI in children 
may not be apparent even after long-term follow-up, and 
requires continuous etiological surveillance. 
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